Burkitt lymphoma

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:healthcare_organization
gptkbp:bfsLayer 3
gptkbp:bfsParent gptkb:healthcare_organization
gptkbp:affects B cells
gptkbp:associated_with EBV infection
gptkbp:caused_by chromosomal translocation
gptkbp:clinical_trial targeted therapies
ongoing research
new therapies
may involve the abdomen
may involve the central nervous system
often presents with jaw lesions
rapid tumor growth
gptkbp:discovered_by 1940s
gptkbp:end_of_life varies by subtype
improved with early treatment
generally favorable with aggressive treatment
gptkbp:first_described_by Dorothy Burkitt
gptkbp:genetic_diversity BC L2 gene
BC L6 gene
MYC gene
https://www.w3.org/2000/01/rdf-schema#label Burkitt lymphoma
gptkbp:is_often_used_in gptkb:Person
gptkbp:named_after Dr. Denis Burkitt
gptkbp:occurs_in higher in males
increased in certain regions
gptkbp:origin gptkb:Africa
gptkb:New_Guinea
gptkbp:research_focus environmental factors
genetic factors
viral factors
gptkbp:risk_factor malaria
immunosuppression
HIV infection
gptkbp:social_responsibility blood tests
imaging studies
biopsy
highly aggressive
rare in developed countries
associated with endemic malaria
can be curable
more common in equatorial Africa
gptkbp:symptoms abdominal pain
fever
night sweats
swollen lymph nodes
gptkbp:treatment gptkb:vaccine
supportive care
radiation therapy
chemotherapy
stem cell transplant
depends on stage
depends on age
antiviral therapy
depends on overall health
CODOX-M regimen
R-CHOP regimen
high-dose methotrexate
gptkbp:type_of endemic Burkitt lymphoma
immunodeficiency-associated Burkitt lymphoma
sporadic Burkitt lymphoma